The Hematologic Malignancies Program (HMP) is a multidisciplinary, collaborative group of basic, translational, and clinical investigators that includes 74 members (46 primary, 28 associate) from 11 departments. The HMP is led by Robert Z. Orlowski, a laboratory-based physician-scientist with expertise in plasma cell biology, protein homeostasis, and drug resistance; Michael Andreeff, a laboratory-based physician-scientist focusing on lymphoid and myeloid cell biology, apoptotic signaling, and stem cell biology; and Hagop M. Kantarjian, a clinician-scientist who is an authority on clinical and translational leukemia biology. Members of the HMP pursue the goal of enhancing our understanding of the pathobiology of hematologic malignancies, and leveraging this new knowledge to develop effective personalized, targeted treatment strategies that ultimately will enable us to cure all patients with these diseases. To achieve this goal, the HMP has the following specific aims:
Aim 1 : To study the epigenome and identify novel drivers of malignant disease and to develop therapies targeted to these features;
Aim 2 : To develop antibodies, vaccines, and adoptive cellular immunotherapies that boost immune recognition and eliminate malignant cells;
Aim 3 : To define microenvironmental influences on tumor biology and drug resistance that modulate biomarkers and regulate chemosensitivity;
and Aim 4 : To validate novel therapies in preclinical models and translate them in a rational, biomarker-driven approach to maximize their impact upon patient outcomes. Program annual direct peer-reviewed funding totals $6.7M, of which $3.8M (57%) is from the National Cancer Institute, including a SPORE in Leukemia. The HMP is leveraging strategic industry alliances and the MD Anderson Moon Shots Program to enhance the breadth of investigator-initiated translational studies and to strengthen understanding of basic biology of these malignancies. Over the last six years, HMP investigators have authored more than 2017 publications where 1126 (56%) represent intra-programmatic collaborations, 545 (27%) represent inter-programmatic collaborations, and 1192 (59%) represent inter- institutional collaborations. Fifty-one percent of publications have appeared in journals with IF >5 and 20% in journals with IF >10, including Cancer Cell, N Engl J Med, and Lancet Oncol. Program members utilized 14 shared resources. During the past grant period, program members contributed significantly to regulatory approval of multiple agents for hematologic malignancies, including small-molecule inhibitors of Bruton tyrosine kinase, BCR/ABL, B-cell CLL/lymphoma 2, and Janus kinase 2 as well as immunotherapies targeting CD19 and other moieties.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997880
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications